DAFTAR PUSTAKA

Abu Samaan, T.M., Samec, M., Liskova, A., Kubatka, P. and Büsselberg, D., 2019. Paclitaxel's mechanistic and clinical effects on breast cancer. *Biomolecules*, *9*(12), p.789.

Arsita, E. V. (2022). *Efek Delesi GSTM1 Menggunakan CRISPR Single Guide RNA Tunggal dan Ganda pada Viabilitas Sel 4T! yang Diterapi Paclitaxel, Kajian pada Exon yang Sama*.

Aysola, K., Desai, A., Welch, C., Xu, J., Qin, Y., Reddy, V., Matthews, R., Owens, C., Okoli, J., Beech, D.J. and Piyathilake, C.J., 2013. Triple Negative Breast Cancer-An Overview. Hereditary genetics: current research, 2013.

Berger, E.R. et al. (2021) 'Immunotherapy treatment for triple negative breast cancer', Pharmaceuticals, 14(8), p. 763. doi:10.3390/ph14080763.

Blajeski, A.L., Kottke, T.J. and Kaufmann, S.H., 2001. A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines. *Experimental cell research*, *270*(2), pp.277-288.

Bradford, H., Advait, L. and Kulkarni, A.B., 2009. Overview: Generation of Gene Knockout Mice. *Current Protocols in Cell Biology*, *44*(19.12), pp.19-1

Campbell, K.J., Dhayade, S., Ferrari, N., Sims, A.H., Johnson, E., Mason, S.M., Dickson, A., Ryan, K.M., Kalna, G., Edwards, J. and Tait, S.W., 2018. MCL-1 is a prognostic indicator and drug target in breast cancer. *Cell death & disease*, *9*(2), pp.1-14.

Criscitiello, C., Azim Jr, H.A., Schouten, P.C., Linn, S.C. and Sotiriou, C., 2012. Understanding the biology of triple-negative breast cancer. *Annals of oncology*, *23*, pp.vi13-vi18.

Dent, R., Trudeau, M., Pritchard, K.I., Hanna, W.M., Kahn, H.K., Sawka, C.A., Lickley, L.A., Rawlinson, E., Sun, P. and Narod, S.A., 2007. Triple-negative breast cancer: clinical features and patterns of recurrence. *Clinical cancer research*, *13*(15), pp.4429-4434.

Dexter, D.L., Kowalski, H.M., Blazar, B.A., Fligiel, Z., Vogel, R. and Heppner, G.H., 1978. Heterogeneity of tumor cells from a single mouse mammary tumor. *Cancer research*, *38*(10), pp.3174-3181.

Farkas, D.H. and Holland, C.A., 2009. Overview of molecular diagnostic techniques and instrumentation. In *Cell and Tissue based Molecular Pathology* (pp. 19-32). Churchill Livingstone.

Global Cancer Data (2020). Globocan 2020: New Global Cancer Data, UICC. Available at: https://www.uicc.org/news/globocan-2020-new-global-cancer-data (Accessed: 10 November 2023).

Hall, B., Limaye, A. and Kulkarni, A.B. (2009) 'Overview: Generation of gene knockout mice', Current Protocols in Cell Biology, 44(1). doi:10.1002/0471143030.cb1912s44.

Hsu, P.D., Lander, E.S. and Zhang, F., 2014. Development and applications of CRISPR-Cas9 for genome engineering. *Cell*, *157*(6), pp.1262-1278.

Jordan, M.A., Toso, R.J., Thrower, D. and Wilson, L., 1993. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. *Proceedings of the National Academy of Sciences*, *90*(20), pp.9552-9556.

Kathawala, R.J., Gupta, P., Ashby Jr, C.R. and Chen, Z.S., 2015. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. *Drug resistance updates*, *18*, pp.1-17.

Kordias, D. et al. (2022) 'Omics analysis of Chemoresistant triple negative breast cancer cells reveals novel metabolic vulnerabilities', Cells, 11(17), p. 2719. doi:10.3390/cells11172719.

Kumar, H. et al. (2023) 'A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer', Journal of Advanced Research [Preprint]. doi:10.1016/j.jare.2023.02.005.

Ma, F., Li, H., Wang, H., Shi, X., Fan, Y., Ding, X., Lin, C., Zhan, Q., Qian, H. and Xu, B., 2014. Enriched CD44+/CD24− population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). *Cancer letters*, *353*(2), pp.153-159.

Nedeljković, M. and Damjanović, A., 2019. Mechanisms of chemotherapy resistance in triple-negative breast cancer—how we can rise to the challenge. *Cells*, *8*(9), p.957.

Old Dominion University, 2021.Literature Review Research. [online] Old Dominion University Library. Available at: <https://guides.lib.odu.edu/c.php?g=966167&p=7021863> [Accessed 24 July 2022].

Page, M.J. et al. (2021) 'The Prisma 2020 statement: An updated guideline for reporting systematic reviews', BMJ [Preprint]. doi:10.1136/bmj.n71.

Prayuni, K., Razari, I. and Yuliwulandari, R. (2019) 'Glutathione S-transferase M1 and T1 null allele frequencies among Indonesian ethnics toward improved

disease risk assessment', Environmental Toxicology and Pharmacology, 65, pp. 14–17. doi:10.1016/j.etap.2018.10.008.

Pulaski, B.A., Clements, V.K., Pipeling, M.R. and Ostrand-Rosenberg, S., 2000. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon γ. *Cancer Immunology, Immunotherapy*, *49*(1), pp.34-45.

Robey, R.W., Pluchino, K.M., Hall, M.D., Fojo, A.T. and Bates, S.E., 2018. Gottesman, structure of p-glycoprotein reveals a molecular basis for poly-specific drug binding. *Nat Rev Cancer*, *18*(7), pp.452-464.

Sheth, V.H. et al. (2022) 'Development and validation of a risk-of-bias tool for assessing in vitro studies conducted in dentistry: The quin', The Journal of Prosthetic Dentistry [Preprint]. doi:10.1016/j.prosdent.2022.05.019

Shetti, D., Zhang, B., Fan, C., Mo, C., Lee, B.H. and Wei, K., 2019. Low dose of paclitaxel combined with XAV939 attenuates metastasis, angiogenesis and growth in breast cancer by suppressing Wnt signaling. Cells, 8(8), p.892.

Swartz, M.K. (2011) "The prisma statement: A guideline for systematic reviews and meta-analyses," Journal of Pediatric Health Care, 25(1), pp. 1–2. Available at: https://doi.org/10.1016/j.pedhc.2010.09.006.

Shimomura, M., Yaoi, T., Itoh, K., Kato, D., Terauchi, K., Shimada, J. and Fushiki, S., 2012. Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines. *International journal of oncology*, *40*(4), pp.995-1004.

Simões-Wüst, A.P., Schürpf, T., Hall, J., Stahel, R.A. and Zangemeister-Wittke, U., 2002. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. *Breast cancer research and treatment*, *76*(2), pp.157-166.

Srinivas, P.R., 2019. Introduction to Protein Electrophoresis. In *Electrophoretic Separation of Proteins* (pp. 23-29). Humana Press, New York, NY.

Tangkheunkan, P., Harncharoen, K., Thanasitthichai, S., Tiwawech, D., Purisa, W., Saelee, P. and Wattanalai, R., 2020. Frequency and association of GSTM1 and GSTT1 gene polymorphisms with survival in breast cancer patients. *Asian Pacific Journal of Cancer Prevention: APJCP*, *21*(8), p.2251.

Tulsyan, S., Mittal, R.D. and Mittal, B., 2016. The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment. *Pharmacogenomics and personalized medicine*, *9*, p.47.

Uman, L., 2011. Systematic Reviews and Meta-Analyses. Journal of the Canadian of Child and Adolescent Psychiatry, [online] 20(1), pp.57-59. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024725/> [Accessed 24 July 2022].

Vaupel, P., 2008. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. *The oncologist*, *13*(S3), pp.21-26.

Wardhani, B.W. et al. (2019) 'Decreased sensitivity of several anticancer drugs in TMEPAI knockout triple-negative breast cancer cells', Medical Journal of Indonesia, 28(2), pp. 110–5. doi:10.13181/mji.v28i2.2687

Wanderley, C.W., Colon, D.F., Luiz, J.P.M., Oliveira, F.F., Viacava, P.R., Leite, C.A., Pereira, J.A., Silva, C.M., Silva, C.R., Silva, R.L. and Speck-Hernandez, C.A., 2018. Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent MannerPaclitaxel Drives TAMs to an M1 Profile. *Cancer research*, *78*(20), pp.5891-5900.

Weaver, B.A., 2014. How Taxol/paclitaxel kills cancer cells. *Molecular biology of the cell*, *25*(18), pp.2677-2681.

Xiang, L., Liu, Z.H., Huan, Q., Su, P., Du, G.J., Wang, Y., Gao, P. and Zhou, G.Y., 2012. Hypoxia-inducible factor-2a is associated with ABCG2 expression, histology-grade and Ki67 expression in breast invasive ductal carcinoma. *Diagnostic Pathology*, *7*(1), pp.1-6.

Zhang, J., Wu, Y., Hu, X., Wang, B., Wang, L., Zhang, S., Cao, J. and Wang, Z., 2017. GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer. *Oncotarget*, *8*(62), p.105905.